Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Domino's Pizza, Inc. (DPZ) Price & Performance

BioNTech SE - ADRTrade
Domino's Pizza, Inc.Trade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Domino's Pizza, Inc. — how do they compare? BioNTech SE - ADR trades at $90.14 (market cap $22.86B), while Domino's Pizza, Inc. trades at $315.41 (market cap $10.31B). The key difference: BioNTech SE - ADR is far larger — about 2.2× Domino's Pizza, Inc.'s market cap, and Domino's Pizza, Inc. pays a 2.57% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BNTXDPZ
Market Cap
$22.86B$10.31B
Sector
HealthConsumer Cyclical
52-Week High
$119.34$485.53
52-Week Low
$83.89$282.89
Enterprise Value
$6.53B$15.21B
Dividend Yield
2.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.

The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.

Domino's Pizza, Inc.

Domino's Pizza (DPZ) trades at $309.85, up 3.47% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of $4.13, missing expectations, but maintains strong profitability with a net margin of 11.89%. Recent news includes CEO succession and new product launches, while analyst consensus remains bullish with a $380.31 price target.

DPZ offers steady growth and a 2.66% dividend yield, but faces risks from slowing same-store sales and high debt. The stock's valuation at 17.84x P/E is reasonable, yet competitive pressures and macroeconomic headwinds warrant caution. Upside potential exists if Q2 earnings beat expectations and new leadership reinvigorates growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Domino's Pizza, Inc.

Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.

Read more on DPZ